![Pierre Fabre and Hill Dermaceuticals, Inc. Announce a Strategic Commercial Partnership for TOLAK® (fluorouracil) Cream 4% in the USA and Beyond Pierre Fabre and Hill Dermaceuticals, Inc. Announce a Strategic Commercial Partnership for TOLAK® (fluorouracil) Cream 4% in the USA and Beyond](http://mma.prnewswire.com/media/474857/Hill_Dermaceuticals_Logo.jpg)
Pierre Fabre and Hill Dermaceuticals, Inc. Announce a Strategic Commercial Partnership for TOLAK® (fluorouracil) Cream 4% in the USA and Beyond
![Pierre Fabre and Hill Dermaceuticals, Inc. Announce a Strategic Commercial Partnership for TOLAK® (fluorouracil) Cream 4% in the USA and Beyond Pierre Fabre and Hill Dermaceuticals, Inc. Announce a Strategic Commercial Partnership for TOLAK® (fluorouracil) Cream 4% in the USA and Beyond](http://mma.prnewswire.com/media/474856/Pierre_Fabre_Logo.jpg?p=facebook)
Pierre Fabre and Hill Dermaceuticals, Inc. Announce a Strategic Commercial Partnership for TOLAK® (fluorouracil) Cream 4% in the USA and Beyond
![Pierre Fabre and Hill Dermaceuticals, Inc. announce a strategic commercial partnership for TOLAK® (fluorouracil) Cream 4% in the USA and beyond | Hill Dermaceuticals Pierre Fabre and Hill Dermaceuticals, Inc. announce a strategic commercial partnership for TOLAK® (fluorouracil) Cream 4% in the USA and beyond | Hill Dermaceuticals](https://www.hillderm.com/wp-content/uploads/2018/07/Tolak.png)
Pierre Fabre and Hill Dermaceuticals, Inc. announce a strategic commercial partnership for TOLAK® (fluorouracil) Cream 4% in the USA and beyond | Hill Dermaceuticals
![PDF) Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome PDF) Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome](https://i1.rgstatic.net/publication/346162747_Use_of_complete_clearance_for_assessing_treatment_efficacy_for_5-fluorouracil_interventions_in_actinic_keratoses_how_baseline_lesion_count_can_impact_this_outcome/links/600d6f1592851c13fe32aefe/largepreview.png)